Clinical trials: Malignancies Multiple
Ovarian Cancer
Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer
This trial will provide data on the safety and efficacy of pegfilgrastim, in terms of duration of grade 4 neutropenia, when administered on the last day or the day after a multi-day, myelosuppressive chemotherapy regimen for…
- Trial name
- NCT00113789
- Testing
- PI Discretion
- Volunteers
- 21 people
- Sponsor
- Amgen
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03087591
- Testing
- Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy before donor stem cell transplant in treating patients with hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT02566304
- Testing
- Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Primary Myelofibrosis, Thrombocytosis
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum tolerated dose and/or Recommended Phase II dose of the…
- Conditions
- Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT01787552
- Testing
- LDE225, INC424
- Where
- 18 sites in Australia, Belgium and 9 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Intrahepatic Cholangiocarcinoma
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
This is a single-arm, open-label, multi-center Phase II clinical trial intended to observe and evaluate the efficacy and safety of famitinib malate in treating iCCA(Intrahepatic Cholangiocarcinoma ) patients with FGFR2 genetic…
- Trial name
- NCT04479904
- Testing
- Famitinib
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-muscle-invasive Bladder Cancer
A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). Bladder cancer has the highest recurrence rate of any malignancy, often as high as 70% within 5 years…
- Trial name
- ANTICIPATE X (NCT03664258)
- Testing
- Xpert Bladder Cancer Monitor
- Where
- 13 sites in Austria, Czechia and 7 more
- Volunteers
- 852 people
- Sponsor
- Cepheid
Prostate Cancer
Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.
This is a prospective single center trial to examine the rates of cancer diagnosis when using computerized software to target suspicious lesions within the prostate identified on mpMRI.
- Trial name
- NCT01964638
- Testing
- Targeted Biopsy
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- NYU Langone Health
Cancer
Supporting Families In Coping With Parental Cancer: A Multi-Site Randomized Controlled Trial
The goal of this behavioral research study is to learn about the effect of a parent support intervention on cancer patients' and their family caregivers' mental wellbeing, and family functioning.
- Trial name
- NCT07852858
- Testing
- Parent Support Intervention
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma (MM), Multiple Myeloma Refractory
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM).
- Conditions
- Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- CORE-MM (NCT07637578)
- Testing
- Elranatamab, Tocilizumab
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- SCRI Development Innovations, LLC
Soft Tissue Sarcoma
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.
- Trial name
- NCT02449343
- Testing
- Anlotinib
- Where
- 25 sites in China
- Volunteers
- 233 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Peripheral T-Cell Lymphoma
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
This is a prospective single-arm, multicenter, phase Ib clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.
- Trial name
- NCT05083208
- Testing
- Parsaclisib, Chidamide
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Henan Cancer Hospital
Multiple Myeloma
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or…
- Trial name
- NCT02206425
- Testing
- Melphalan, Prednisone, Cyclophosphamide
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated…
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT04018248
- Testing
- BR101801 (Phase Ia), BR101801 (Phase Ib)
- Where
- 9 sites in United States, South Korea
- Volunteers
- 26 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Endometrial Carcinoma, P53 Mutation
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
This is an umbrella, two-arm, multi-stage, phase II trial. The purpose of the trial in the early stage cohort is to determine if EBRT improves disease free survival (defined as the time from random assignment to disease…
- Conditions
- Endometrial Carcinoma, P53 Mutation, Serous Carcinoma
- Trial name
- CAN-STAMP (NCT04159155)
- Testing
- External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto
Cancer, Risk Factors in Latinos
Determinants of Multiple Health Risk Behaviors Among Latinos
The goal of this research study is to learn how cultural, environmental, and interpersonal experiences, as well as personal thoughts and feelings, influence cancer risk behaviors among Latino residents of Houston, Texas.
- Trial name
- NCT01479257
- Testing
- Questionnaires, Accelerometer, Smart Phone
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT00536601
- Testing
- etoposide, cyclophosphamide, carmustine
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Roswell Park Cancer Institute
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
EHealth Educational Intervention to Improve Self-Management and Coping Behaviors Among Cancer Patients
Brief Summary This study evaluates the effectiveness of a structured eHealth-based educational and support intervention in improving self-management practices and psychological coping behaviors among adult cancer patients.
- Trial name
- EHCancer (NCT07457112)
- Testing
- Structured eHealth Educational Intervention
- Where
- Egypt
- Volunteers
- 212 people
- Sponsor
- Zagazig University
Multiple Myeloma, Non-Hodgkin Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
- Trial name
- NCT04045028
- Testing
- Tiragolumab, Daratumumab/rHuPH20, Rituximab
- Where
- 14 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Hematologic Malignancy
CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT
The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.
- Trial name
- CD45RADLIHaplo (NCT05943067)
- Testing
- CD45RA depleted donor lymphocyte infusion (DLI)
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Multiple Myeloma
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
This is a single-arm, open-label study evaluating the safety, tolerability and efficacy of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in patients with RRMM.
- Trial name
- CC-220 (NCT05560399)
- Testing
- Iberdomide, Elotuzumab, Dexamethasone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.